Cancer Medicine最新文献

{"title":"Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck","authors":"Chang Jiang,&nbsp;Shengjin Dou,&nbsp;Yu Wang,&nbsp;Wen Jiang,&nbsp;Lulu Ye,&nbsp;Rongrong Li,&nbsp;Xiaolong Fu,&nbsp;Lin Zhang,&nbsp;Guopei Zhu","doi":"10.1002/cam4.71235","DOIUrl":"10.1002/cam4.71235","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Amplification of 11q13 (FGF3/4/19, CCND1) is frequently observed in head and neck squamous cell carcinoma (HNSCC). However, there is a lack of research investigating 11q13 amplification as a prognostic marker for patients with locally advanced (LA) HNSCC who undergo postoperative radiotherapy (PORT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This retrospective study included consecutive patients of LA-HNSCC who underwent radical surgical resection and PORT. The 11q13 amplification was tested by next-generation Sequencing (NGS) or fluorescent in situ hybridization (FISH). Propensity score matching (PSM) was used to match the amplification and wild-type groups. Univariate and multivariate analyses were conducted using Kaplan–Meier and Cox regression. Recurrence patterns and phenotypes in the amplification group were also assessed. Statistical analyses were performed using R software, with a <i>p</i>-value of &lt; 0.05 considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 70 patients were included (35 in the 11q13 amplification group and 35 in the wild-type group). Patients with 11q13 amplification exhibited significantly worse disease-free survival (DFS) (3-year DFS: 21.0% vs. 52.6%; <i>p</i> &lt; 0.0019) and overall survival (OS) (3-year OS: 46.4% vs. 66.7%; <i>p</i> = 0.032) compared to wild-type patients. The recurrence pattern in the amplification group showed an approximately equal proportion of local-regional recurrence (LRR) and distant metastases (DM). The LRR predominantly occurred within the 60 Gy radiation field. Multivariate analyses revealed that 11q13 amplification significantly associated with worse DFS (<i>p</i> &lt; 0.001) and OS (<i>p</i> = 0.007).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>LA-HNSCC patients with 11q13 amplification exhibited significantly worse DFS and OS compared to wild-type patients. The recurrence pattern in the 11q13 amplification group was primarily characterized by in-field recurrences within the 60 Gy dose.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Profile of Non-Hodgkin's Lymphomas Seen at Kinshasa University Clinics From 2012 to 2022","authors":"Mbwamulungu Nakweti Julia,&nbsp;Azako David,&nbsp;Pezo Serge,&nbsp;Bokambadja Fabrice,&nbsp;Kapour Kieng Germain,&nbsp;Bompangue Nkoko Didier,&nbsp;Kisile Olive,&nbsp;Lebwaze Massamba Bienvenu,&nbsp;Kabongo Mpolesha Jean-Marie","doi":"10.1002/cam4.71254","DOIUrl":"10.1002/cam4.71254","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers whose global incidence has been increasing in recent years. In the DRC, the absence of a national cancer registry is a serious handicap to the epidemiological evaluation of NHL. There is still a lack of knowledge about this pathology among the population and health professionals. An observational survey of the country's hospitals is enough to note the absence of protocols for the management of NHL. The objective of this study is to determine the epidemiological aspects of non-Hodgkin lymphoma in the DRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A descriptive cross-sectional study, conducted at the University Clinics of Kinshasa, from 2012 to 2022. The chi-square correlation test is used to compare proportions with the 95% confidence interval (<i>α</i> = 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of a total of 2070 cancer cases, 51 NHL cases were recorded, or 2.5%. 98% of the recorded cases were B-cell lymphomas compared to 2% T-cell lymphomas. 80% of cases were aggressive and 20% were indolent. 55% of cases were male versus 45% female, with a sex ratio of 1.2. The age of the patients ranged from 3 to 80 years, with a mean age of 42 years and a median of 45 years. The histological type DLBCL was predominant in 63% of cases. 59% of cases involved lymph nodes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers whose global incidence has been increasing in recent years, with the outbreak of environmental and infectious factors. Knowledge of epidemiological aspects contributes to the improvement of the fight against NHL in the DRC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer","authors":"Fleury Augustin Nsole Biteghe,&nbsp;Neelakshi Mungra,&nbsp;Zaria Malindi,&nbsp;Nyangone Ekome Toung Chalomie,&nbsp;Ketum Ateh Stanislas,&nbsp;Sayeda Yasmin-Karim,&nbsp;G. Mike Makrigiorgos,&nbsp;Fallon Ester Chipidza,&nbsp;Olusiji Alex Akinrinmade,&nbsp;Srinivas Sridhar,&nbsp;Stefan Barth,&nbsp;Wilfred Ngwa","doi":"10.1002/cam4.71255","DOIUrl":"10.1002/cam4.71255","url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER-2) expression. It disproportionately affects women of African descent and has a poor clinical prognosis attributed to its acute heterogeneity, thereby causing elevated mortality rates. Due to the lack of well-defined molecular targets in TNBC, treatment relies heavily on a trimodality approach (surgery, radiotherapy, and chemotherapy), despite growing evidence of adverse effects and disease relapses. Therefore, there is an urgency to identify targetable aberrations for more effective approaches capable of selectively detecting and killing targeted cells while sparing healthy tissues. The emergence of monoclonal antibodies (mAbs) targeting tumor-associated antigens (TAAs), which can be used as a carrier to deliver highly cytotoxic drugs, raised hopes that antibody-drug conjugates (ADCs) might solve the toxicity-therapy challenge by shifting the balance more toward beneficial therapeutic efficacy. Despite their therapeutic benefits, their clinical translation is limited by key developmental barriers, including immune-related adverse events. To address these limitations, a novel approach using antibody-photoconjugates (APCs) was developed for photoimmunotherapy (PIT) applications, whereby local exposure to near-infrared (NIR) light induces targeted phototoxic damage, culminating in apoptotic, necrotic, and immunogenic cell death (ICD) with minimal toxicities. Therefore, this review highlights the potential of PIT as an inherently safer and efficient light-dependent therapeutic option for treating TNBC.</p><p><b>Trial Registration:</b> NCT06449222</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017","authors":"Marko Damm,&nbsp;Miriam Heinig,&nbsp;Jonas Rosendahl,&nbsp;Patrick Michl,&nbsp;Ulrike Haug,&nbsp;Sebastian Krug","doi":"10.1002/cam4.71248","DOIUrl":"10.1002/cam4.71248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>With a rising incidence and unchanged poor prognosis, pancreatic cancer is increasingly becoming a focus of gastroenterological oncology, but there is a lack of real-world data. The aim of the current study was to investigate trends in survival and treatment patterns by analyzing German health claims data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pancreatic cancer patients diagnosed between 2010 and 2017 were identified from the German Pharmacoepidemiological Research Database (GePaRD, approximately 20% of the German population). Data on demographics, tumor treatment within 1 year after diagnosis, and survival were extracted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study population comprised 23,339 patients with a median age of 74 years (IQR 66–80) and 44% with localized and 56% with metastatic disease. Overall, 52.4% received any chemotherapy, and curative intended resection was performed in 28.3%. Neoadjuvant and adjuvant therapy were performed in 4.4% and 58.7% of the cases, respectively. The median overall survival of the whole study population was 7.84 months. Patients diagnosed in the most recent period (2014–2017) had a significantly better prognosis (8.20 months (95% CI 7.97–8.43)) than patients who were diagnosed in the earlier period (2010–2013) (7.54 months (95% CI 7.31–7.70), <i>p</i> &lt; 0.001), with an age-, sex-, and stage-adjusted hazard ratio of 0.87 (95% CI 0.85–0.9). Over time, the most pronounced treatment trends have affected patients with localized disease, with increasing frequency of resection and neoadjuvant therapy and decreasing frequency of best supportive care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This comprehensive insight into survival and treatment of pancreatic cancer in Germany shows presumably medically beneficial therapy trends with, however, only marginal improvements in prognosis to date.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer-Associated Thrombosis (CAT): A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets","authors":"Mehran Ghasemzadeh,&nbsp;Nazanin Heidari,&nbsp;Jalal Naghinezhad,&nbsp;Alireza Ghasemzadeh,&nbsp;Ehteramolsadat Hosseini","doi":"10.1002/cam4.71270","DOIUrl":"10.1002/cam4.71270","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Induction of programmed cell demise against tumors that achieves selective targeting of the cancerous state without side effects on healthy tissues and cells is the most challenging therapeutic goal to eradicate cancer progression. In this regard, several BH3-mimetic drugs have been designed to induce apoptosis in cancer cells with acceptable specificity and fewer adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Implications</h3>\u0000 \u0000 <p>Taking all considerations into account, even the latest versions of -BH3 mimetics or some other systemic anticancer drugs may affect platelets, mainly manifested by thrombocytopenia in cancer patients who are per se at major risk of hemostatic complications. This is mainly due to the fact that platelets, as anucleated cells, are more vulnerable to apoptosis, especially induced by earlier versions of BH3-mimetics. On the other hand, the cancerous state, particularly in its aggressive conditions, is usually associated with the risk of thrombosis and thromboembolism. Therefore, given that some earlier versions of BH3-mimetics have the potential to simultaneously damage platelets and cancer cells, they may be considered as a therapeutic choice for the treatment of cancer-associated thrombosis (CAT). However, this is subject to the design of a specific platform of drug carriers that supports cancer targeting without interfering with other tissues and cells. The critical review presented here first provides an overview of the various BH3-mimetic drugs available, highlighting ongoing development to enhance their safety and efficacy. Then, by introducing studies on the direct delivery of BH3-mimetics, this review finally proposes an innovative approach for the “conserved conveyance” of drugs to effectively cotarget cancer cells and activated platelets at the site of CAT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Notably, the main advantage of the proposed drug delivery system presented here is its minimal interference with natural hemostasis, where the drug is expected to attack only tumor cells and CAT, without affecting circulating platelets required for physiological thrombus formation and proper hemostasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71270","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR Mutation Detection in Whole Slide Images of Non-Small Cell Lung Cancers Using a Two-Stage Deep Transfer Learning Approach","authors":"Michele Zanoletti,&nbsp;Filippo Ugolini,&nbsp;Laila El Bachiri,&nbsp;Valeria Pasini,&nbsp;Marco Laurino,&nbsp;Francesco De Logu,&nbsp;Eleonora Melissa,&nbsp;Carolina Marchi,&nbsp;Maria Colombino,&nbsp;Daniela Massi,&nbsp;Guido Rindi,&nbsp;Camilla Eva Comin,&nbsp;Giuseppe Palmieri,&nbsp;Antonio Cossu","doi":"10.1002/cam4.71249","DOIUrl":"10.1002/cam4.71249","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung cancer (LC) is the leading cause of cancer death worldwide. Non-small cell lung cancer is the most frequent and includes adenocarcinoma and squamous cell carcinoma. Currently, LC treatment is based on tumor molecular profiling. LC may display Epidermal Growth Factor Receptor (EGFR) gene mutation. Detecting mutations in the EGFR gene is crucial for the tyrosine kinase inhibitory therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study used a computer-based methodology with two Convolutional Neural Networks (CNNs) based on InceptionResNet-V2, applied to Whole Slide Images, to distinguish healthy from cancerous tissue and then EGFR mutated tumor tissue samples. We also integrated an Explainable AI technique (Grad-CAM) to clearly visualize insights into the model's decision-making process. The analysis was conducted on 259 LC cases collected from three different centers (Florence, Rome, and Sassari).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This methodology achieved an accuracy of 96.17% in distinguishing healthy from cancerous tissue, with specificity of 87.89%, sensitivity of 98.43%, an F1 score of 97.59% and an AUC of 0.99. Additionally, Cohen's Kappa indicated a consistency of 0.7982, and the confusion matrix showed a correct classification rate of 96.2%. For EGFR mutation detection in cancer tissue, slide-level performance after aggregation reached an accuracy of 76.67% with specificity of 80.77%, sensitivity of 73.53%, an F1 score of 78.12%, a consistency of 0.5583 of Cohen's Kappa and an AUC of 0.77. The confusion matrix showed 76.7% as a correct classification rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The two tested CNNs showed potential for assisting LC diagnosis, especially in distinguishing healthy from tumor tissue. While the direct detection of EGFR mutational status remains challenging, the results suggest that relevant predictive signals can still be extracted from routine H&amp;E slides.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12445122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focal Adhesion Kinase Intersects With the BRD4-MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer","authors":"Rongbo Han,&nbsp;Junfeng Shi,&nbsp;Kai Cheng,&nbsp;Zian Wang,&nbsp;Yecang Chen,&nbsp;Orion Spellecy,&nbsp;Abu Saleh Mosa Faisal,&nbsp;Isha Aryal,&nbsp;Jinfei Chen,&nbsp;Rolf Craven,&nbsp;Olivier Thibault,&nbsp;Lauren Baldwin,&nbsp;Lawrence D. Brewer,&nbsp;Sonia Erfani,&nbsp;Chi Wang,&nbsp;Zhenheng Guo,&nbsp;Eric Chen,&nbsp;Burton Yang,&nbsp;Frederick Ueland,&nbsp;Ruihua Guo,&nbsp;Xiuwei Yang","doi":"10.1002/cam4.71227","DOIUrl":"10.1002/cam4.71227","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) remains one of the leading causes of cancer-related death worldwide due to the lack of effective therapies. Here we explored the clinical basis and therapeutic promise of the integrin-focal adhesion kinase (FAK)-dependent pathway for CRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Our bioinformatic and histological analyses showed that FAK was markedly upregulated at both mRNA and protein and signaling levels in the two CRC patient cohorts. Particularly, the portion of carcinomas carrying active FAK (Y³⁹⁷phosphorylation) increased by threefold from stage I to III/IV tumors or metastatic lesions. Consistent with this clinic landscape, FAK inhibition via knockdown or chemical inhibitors suppressed tumor cell growth largely in the subset of CRC cell lines with low MYC expression. In contrast, the FAK inhibition was less effective in the cell line pool with high MYC expression. The resistance to FAK targeting diminished upon a co-inhibition of BRD4 via BET inhibitors. It coincided with an induction of cell cycle arrest at G1-S and G2-M phases, elevated apoptosis and chemosensitivity (paclitaxel and oxaliplatin), and impaired stemness. Mechanistically, the BET inhibitor induced an EMT-like phenotype, tilting tumor cell dependence toward the integrin-FAK axis. Moreover, inhibiting FAK alone or in combination with SRC or BRD4 markedly suppressed cell motility and the YAP or MYC activation, and restored the expression of the long isoform BRD4. Also, co-genomic/genetic dysregulations of FAK and YAP1 or SRC strongly correlated with poor disease-free patient survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, our study highlights the potent pro-malignant role of the integrin-FAK axis in CRC, fueling its targeting as a single agent or synthetic lethal-based therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and Mid-Term Outcomes of Proximal Gastrectomy With Double-Tract Reconstruction Versus Total Gastrectomy in Early-Stage Proximal Gastric Cancer","authors":"Ying Liu,&nbsp;Mingfang Yan,&nbsp;Zhaoyan Lin,&nbsp;Shenghong Wei,&nbsp;Yangming Li,&nbsp;Zhenmeng Lin,&nbsp;Xingfa Chen","doi":"10.1002/cam4.71258","DOIUrl":"10.1002/cam4.71258","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Total gastrectomy (TG) is the predominant approach for proximal gastric cancer; however, it frequently leads to various postoperative nutritional and metabolic disorders. Recently, double-tract reconstruction (DTR) following proximal gastrectomy (PG) has been developed to preserve gastric function and reduce postoperative reflux esophagitis. This study aimed to compare the outcomes of PG-DTR with those of TG in patients with proximal gastric cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with clinically staged cT1 to cT2 proximal gastric cancer who underwent either PG-DTR or TG with Roux-en-Y reconstruction (TG-RY) were enrolled. Propensity score matching (PSM) was applied to reduce confounding bias. Surgical outcomes, nutritional status, reflux esophagitis, and prognosis were prospectively analyzed. Quality of life (QOL) was assessed at 3, 6, and 12 months postoperatively using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After PSM, 93 patients were included in each group (PG-DTR and TG-RY). The PG-DTR group had fewer retrieved lymph nodes than the TG-RY group. No significant differences were observed between the groups in operative time, blood loss, postoperative complications, length of hospital stay, reflux esophagitis, overall survival (OS), or disease-free survival (DFS). Female sex, preoperative BMI, TG-RY procedure, and severe postoperative complications (POCs) were identified as independent risk factors for malnutrition at 3 months postgastrectomy. Postoperatively, the TG-RY group exhibited significantly lower levels of hemoglobin, total protein, and albumin than the PG-DTR group. No differences were observed in postoperative QOL between the two groups, except for greater weight loss in the TG-RY group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared to TG-RY, PG-DTR was associated with improved postoperative nutritional status, including better body weight, hemoglobin, and albumin levels, in patients with early-stage proximal gastric cancer. Additionally, PG-DTR demonstrated comparable short-term outcomes, prognosis, and postoperative QOL to TG-RY, further supporting its viability as a surgical option.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi-Antigen Anti-Leukemic Immune Response”","authors":"","doi":"10.1002/cam4.71261","DOIUrl":"10.1002/cam4.71261","url":null,"abstract":"<p>Gil-de-Gómez, L., Mattei, J.J., Lee, J.H., Grupp, S.A., Reid, G.S.D. and Seif, A.E. (2025), CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi-Antigen Anti-Leukemic Immune Response. Cancer Med, 14: e70508. https://doi.org/10.1002/cam4.70508</p><p>Affiliation number 2 should include “IDIVAL.” It should have read: “Department of Molecular Biology, University of Cantabria School of Medicine-IDIVAL, Santander, Cantabria, Spain.”</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study","authors":"Xiufen Wang,&nbsp;Dahai Wang,&nbsp;Yanxin Sun,&nbsp;Yiling Gan,&nbsp;Juan Li,&nbsp;Xuebing Fu,&nbsp;Yihui Ge,&nbsp;Shuyun Wang,&nbsp;Leirong Wang,&nbsp;Haodong Sun,&nbsp;Haifeng Sun,&nbsp;Yuping Sun,&nbsp;Aiqin Gao","doi":"10.1002/cam4.71260","DOIUrl":"10.1002/cam4.71260","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>HER2 alterations are identified in 2%–4% of lung adenocarcinoma, indicating poor clinical outcomes. Chemotherapy alone (C) or in combination with bevacizumab (BC), immune checkpoint inhibitors (IC), or both (IBC) are standard options in the first-line setting; however, optimal therapy and beneficiary populations remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with Stage IV HER2-altered lung adenocarcinoma from four cancer centers in China were retrospectively analyzed. The patients received C, BC, IC, or IBC as the first-line treatments. Clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated. The tumor immune microenvironment (TIME) characteristics were analyzed to explore the beneficiary populations with different treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IBC treatment generated the longest mPFS and OS among four schemes. Subgroup analyses showed that IBC resulted in longer PFS in patients with brain or bone metastases compared to IC. IBC generated significant benefits in younger patients, nonsmokers, and those with oligometastases versus BC. In patients with low density of PD-1⁺CD8⁺ T-cells or high density of CD163⁺ macrophages in the TIME, IBC treatment resulted in the longest PFS, followed by BC treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>IBC treatment generated optimal efficacy as first-line therapy for HER2-altered lung adenocarcinoma. Patients with low PD1⁺CD8⁺ T-cell or high CD163⁺ macrophage infiltration benefited more from IBC treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}